UNBELIEVABLE: 5 | History Defined

What's Next For Novavax Stock As COVID Vaccine Clears Key Hurdle In US

After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax (NASDAQ: NVAX) can now heave a sigh of relief.

Benzinga · Jun 8, 2022

5 Stocks To Watch For June 8, 2022

Some of the stocks that may grab investor focus today are:

Benzinga · Jun 8, 2022

Novavax COVID-19 shot gets backing from FDA advisory panel

WASHINGTON — Novavax Inc.’s coronavirus vaccine won the support of a panel of U.S. government advisers, paving the way for authorization of another tool to fight the coronavirus.

Tribune News Service · Jun 8, 2022

FDA advisers back Novavax COVID-19 shots as new US option

A more traditional kind of COVID-19 vaccine has moved a step closer to the U.S. market

The Independent UK · Jun 7, 2022

What's Going On With Novavax Stock Today?

Novavax Inc (NASDAQ: NVAX) shares have been halted since the pre-market session as the U.S. Food and Drug Administration holds a meeting to determine the fate of the company's COVID-19 vaccine.

Benzinga · Jun 7, 2022

Novavax's new shot may sway anti-vaxxers

Experts hope the new COVID vaccine, which uses older biotechnology, could help the unvaccinated come around

Salon · Jun 6, 2022

US FDA Concerned over Potential Novavax Myocarditis Risk

The Food and Drug Administration voiced concern Friday about myocarditis being potentially linked to the Novavax Covid-19 vaccine, just as experts are to weigh its use in the United States. The Novavax vaccine is already authorized in other countries, particularly in Europe. In the United States, an independent committee convened…

Asharq Al-Awsat · Jun 4, 2022

Novavax COVID shot effective but carries heart risk, FDA says

Novavax evaluation comes days before key FDA meeting

Axios · Jun 3, 2022

Novavax hopes its COVID shot wins over FDA, vaccine holdouts

Americans may soon get a new COVID-19 vaccine option — a more traditional kind of shot known as a protein vaccine

The Independent UK · Jun 2, 2022

Novavax missed its global moonshot but is angling to win over mRNA defectors

Novavax hitched its wagon to the global coronavirus pandemic. Before most Americans truly grasped the scope of the danger, the small Maryland biotech startup had secured $1.6 billion in U.S. funding for its COVID-19 vaccine. Its moonshot goal: delivering 2 billion shots to the world by mid-2021.

Tribune News Service · May 30, 2022